Announcements Trials
Browse Landscape

Phase

Phase 2 16Phase 1 7Phase NA 4Phase 3 2Phase EARLY_PHASE1 1Phase 4 1Phase 1/2 1

Status

Unknown 1Active not recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Lymphoma 7Lymphoma, Follicular 6Leukemia, Biphenotypic, Acute 6Leukemia 6Lymphoma, Non-Hodgkin 4Lymphoma, Large B-Cell, Diffuse 4Lymphoma, Large-Cell, Immunoblastic 3Leukemia, Myeloid, Acute 3Burkitt Lymphoma 3Prostatic Neoplasms 2Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms 2Multiple Myeloma 2Lymphohistiocytosis, Hemophagocytic 2Leukemia, Lymphocytic, Chronic, B-Cell 2Graft vs Host Disease 2Epstein-Barr Virus Infections 2Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Pneumonia, Pneumocystis 1Pneumonia 1Pain 1Neurotoxicity Syndromes 1Neuroma, Acoustic 1Neoplasms, Plasma Cell 1Neoplasm Metastasis 1Lymphoma, Large-Cell, Anaplastic 1Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 1Leukemia, Myeloid, Chronic-Phase 1

Interventions

Dexamethasone 169Bortezomib 92Lenalidomide 85daratumumab 44Thalidomide 44pomalidomide 43Melphalan 40Cyclophosphamide 33carfilzomib 29Calcium Dobesilate 27Prednisone 19Doxorubicin 16elotuzumab 14isatuximab 12Filgrastim 12ixazomib 11Vincristine 10Peripheral Blood Stem Cell Transplantation 10belantamab mafodotin 9Granulocyte Colony-Stimulating Factor 9Zoledronic Acid 8selinexor 7dexamethasone acetate 7Epoetin Alfa 7Etoposide 6fludarabine 5Cisplatin 5Carmustine 5iberdomide 4Radiotherapy 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Multiple Myeloma × Methylprednisolone × Clear all
NCT04270409 2025-12-12

Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma

Sanofi

Phase 3 Active not recruiting
337 enrolled
Plasma cell

Multiple Myeloma

NCT00002599 2013-12-19

Combination Chemotherapy and Interferon Alfa With or Without Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloma

National Cancer Institute (NCI)

Phase 3 Unknown
750 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡